BioAge Labs, Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Sounds great. Thank you for having us. Just to introduce the company briefly, BioAge is a platform biotech company. We apply the biology of human aging to identify targets for cardiometabolic disease. Our lead program is BGE-102. It's a potential best-in-class NLRP3 inhibitor. We shared data earlier this year from an extended phase I that we ran, where we were thrilled with the profile that emerged across several key dimensions. One was the magnitude of biomarker reductions that we saw in obese, inflamed individuals. Two was the dosing paradigm, with 60 milligrams able to achieve 24 hours of IC90 coverage, and at 120 achieving essentially complete target inhibition at trough, 98%. The safety tolerability profile that we observed, really we thought it was exceptional.

Lastly, one of the key differentiators of this molecule is its tissue distribution and ability to access protected compartments like the CSF as well as the retina, and so that certainly informed our indication strategy that we'll get into in a little bit. So that's our lead program. We have two phase IIs that are ongoing with BGE-102. One is QUELL-CV, which is a dose-ranging trial in obese individuals with elevated inflammation. There, we're going to be looking at cardiometabolic biomarkers, inflammatory biomarkers, teasing out a dose response, and building the safety database over an extended treatment duration, so over 3 months. We'll have that top-line data at the end of this year. We also recently dosed the first patient in our QUELL-DME trial.

This is a trial looking at BGE-102 in diabetic macular edema, and it is similarly 3 months of treatment across 3 arms, so looking at BGE-102 as a monotherapy as well as in combination with VEGF. There, we recently actually announced that we had increased the size and the scope of the trial to power for best-corrected visual acuity. This is now, we are now looking at that as a primary endpoint, visual acuity, with 90% power to show a four-letter improvement. That trial is now enrolling, and we are expecting data by the end of next year.

Yeah. Right. So that is our BGE-102 program.

We also, behind that, are developing a family of APJ agonists. This is, APJ is a target that was derived from our platform. It is one of the most strongly correlated with both longevity as well as preservation of physical function. We showed with a prior molecule very, very nice preservation of muscle integrity in bed rest. Pre-clinically, with APJ agonism, we see a doubling of weight loss on top of a GLP-1 and complete restoration of lean body composition. We are developing both an oral small molecule as well as a parenteral APJ agonist with the goal of addressing both segments of the GLP-1 market.

Mm-hmm. Yeah, so our platform is sort of the central thesis of the company. I think everyone is familiar with biobanking as a concept. It has taken off in recent decades. I think we are very focused on human aging, and the key variable there is time. We partnered with some of the world's leading biobanks that have been following patients for decades, starting from healthy middle age through, in many cases, death, and then charting, doing sort of detailed phenotyping along the way, physical function, cognitive function, and then doing serial sampling as well. So we can now go and follow those samples, apply modern omics technology, and ask the question, what is the biology that is predictive of good outcomes and vice versa, right? That really informed a lot of our therapeutic hypotheses.

Yeah. And maybe just to touch on the collaboration.

Sure. On the platform side, we have a collaboration with Novartis.

This is really around target discovery, where we're looking at the intersection of human sort of healthy aging, and that's our contribution to the collaboration, and they have some very rich exercise intervention datasets. We are trying to identify targets at the intersection of those two things.

Yeah. We also have a collaboration with Eli Lilly, and this is a molecule discovery collaboration.

We are looking for, we are building molecules against novel targets that have emerged out of our platform.